Royalty Pharma Aims to Buy Elan for $6.5 Billion


Feb 27, 2013

RP Management LLC, an investor in royalty streams from pharmaceuticals, offered to buy Elan Corp. for about $6.5 billion, threatening the Irish drugmaker’s plan to embark on its own acquisitions. Read the full story here. 
Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments